<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-id journal-id-type="iso-abbrev">Crit Care</journal-id><journal-title-group><journal-title>Critical Care</journal-title></journal-title-group><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3642593</article-id><article-id pub-id-type="publisher-id">cc12289</article-id><article-id pub-id-type="doi">10.1186/cc12289</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Anti-Xa activities following 5,000 IU and 7,500 IU of s.c. dalteparin in critically ill patients and 5,000 IU in medical patients: a prospective randomized study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Heinz</surname><given-names>GH</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Priglinger</surname><given-names>U</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Pabinger</surname><given-names>I</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib></contrib-group><aff id="I1"><label>1</label>University Clinic of Internal Medicine II, Vienna, Austria</aff><aff id="I2"><label>2</label>University Clinic of Emergency Medicine, Vienna, Austria</aff><aff id="I3"><label>3</label>University Clinic of Internal Medicine I, Vienna, Austria</aff><pub-date pub-type="ppub"><year>2013</year></pub-date><pub-date pub-type="epub"><day>19</day><month>3</month><year>2013</year></pub-date><volume>17</volume><issue>Suppl 2</issue><supplement><named-content content-type="supplement-title">33rd International Symposium on Intensive Care and Emergency Medicine</named-content><named-content content-type="supplement-sponsor">Publication of this supplement was supported by ISICEM</named-content></supplement><fpage>P351</fpage><lpage>P351</lpage><permissions><copyright-statement>Copyright &#x000a9; 2013 Heinz et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Heinz et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://ccforum.com/content/17/S2/P351"/><conference><conf-date>19-22 March 2013</conf-date><conf-name>33rd International Symposium on Intensive Care and Emergency Medicine</conf-name><conf-loc>Brussels, Belgium</conf-loc></conference></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Unfractionated heparin is preferred over LMWH in ICU patients but LMWH is used more frequently in many European ICUs. Thromboprophylaxis with standard doses of nadroparin and enoxaparin has been shown to result in significantly lower anti-Xa in ICU patients when compared with medical patients [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>].</p></sec><sec sec-type="methods"><title>Methods</title><p>ICU patients (SAPS 44 &#x000b1; 16, MV, <italic>n = </italic>44; pressors <italic>n = </italic>32) received 7,500 IU (Group 1, <italic>n = </italic>25) or 5,000 IU dalteparin s.c. (Group 2, <italic>n = </italic>29). Twenty-nine medical patients receiving 5,000 IU dalteparin served as controls (Group 3).</p></sec><sec sec-type="results"><title>Results</title><p>Group 2 had significantly lower areas under the Xa curve (AUC) compared with Groups 1 and 3 (Table <xref ref-type="table" rid="T1">1</xref>). Differences were not significant between Groups 1 and 3. Peak anti-Xa activities (C<sub>max</sub>-anti-Xa) were delayed (t<sub>max</sub>-anti-Xa) in Group 2 compared with Groups 1 and 3 (Table <xref ref-type="table" rid="T1">1</xref>).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Pharmacokinetics</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="center">Group 1 (<italic>n </italic>= 25)<break/>ICU, 7,500 IU</th><th align="center">Group 2 (<italic>n </italic>= 29)<break/>ICU, 5,000 IU</th><th align="center">Group 3 (<italic>n </italic>= 29)<break/>Normal ward, 5,000 IU</th><th align="center"><italic>P </italic>overall</th></tr></thead><tbody><tr><td align="left">AUC-anti-Xa<sub>0-12hours </sub>(U/l<sup>*</sup>hour)</td><td align="center">2.51 (1.15 to 4.61)</td><td align="center">1.27 (1.15 to 4.4)</td><td align="center">2.58 (1.45 to 4.87)</td><td align="center">&#x0003c;0.001<sup>*</sup></td></tr><tr><td align="left">AUC-anti-Xa<sub>12_00 </sub>(U/l<sup>*</sup>hour)</td><td align="center">1.37 (0.58 to 13)</td><td align="center">1.47 (0.65 to 6.3)</td><td align="center">0.89 (0.35 to 3.88)</td><td align="center">0.003<sup>**</sup></td></tr><tr><td align="left">C <sub>max</sub>-anti-Xa (U/l)</td><td align="center">0.29 (0.10 to 0.52)</td><td align="center">0.14 (0.1 to 0.43)</td><td align="center">0.33 (0.14 to 0.65)</td><td align="center">&#x0003c;0.001<sup>***</sup></td></tr><tr><td align="left">t <sub>max</sub>-anti-Xa (hours)</td><td align="center">3 (3 to 12)</td><td align="center">4.5 (1 to 12)</td><td align="center">3 (3 to 6)</td><td align="center">0.017&#x000a7;</td></tr></tbody></table><table-wrap-foot><p>C<sub>max' </sub>peak anti-Xa level; t <sub>max' </sub>time of anti-Xa peak. Medians and range. <sup>*</sup>Group 1 versus 2, <italic>P = </italic>0.001; Group 1 versus 3, <italic>P = </italic>0.51. <sup>**</sup>Group 1 versus 2, <italic>P = </italic>0.96; Group 1 versus 3, <italic>P = </italic>0.045; Group 2 versus 3, <italic>P = </italic>0.13. <sup>***</sup>Group 1 versus 2, <italic>P = </italic>0.001; Group 1 versus 3, <italic>P = </italic>0.29. <sup>&#x000a7;</sup>Group 1 versus 3, <italic>P = </italic>0.09; Group 1 versus 2, <italic>P = </italic>0.8; Group 2 versus 3, <italic>P = </italic>0.018.</p></table-wrap-foot></table-wrap></sec><sec sec-type="conclusions"><title>Conclusion</title><p>In ICU patients a s.c. dose of 5,000 IU dalteparin results in significantly lower Xa activities when compared with normal ward patients. A s.c. dose of 7,500 IU dalteparin in ICU patients resulted in kinetics and peak anti-Xa activities comparable with medical patients receiving 5,000 IU dalteparin.</p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>D&#x000f6;rffler-Melly</surname><given-names>J</given-names></name><name><surname>deJonge</surname><given-names>E</given-names></name><name><surname>dePont</surname><given-names>AC</given-names></name><etal/><article-title>Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors</article-title><source>Lancet</source><year>2002</year><volume>359</volume><fpage>849</fpage><lpage>850</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(02)07920-5</pub-id><pub-id pub-id-type="pmid">11897286</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Priglinger</surname><given-names>U</given-names></name><name><surname>Delle Karth</surname><given-names>G</given-names></name><name><surname>Geppert</surname><given-names>A</given-names></name><etal/><article-title>Prophylactic anticoagulation with enoxaparin: is the subcoutaneous route appropriate in the critically ill?</article-title><source>Crit Care Med</source><year>2003</year><volume>31</volume><fpage>1405</fpage><lpage>1409</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000059725.60509.A0</pub-id><pub-id pub-id-type="pmid">12771610</pub-id></mixed-citation></ref></ref-list></back></article>